Video
Dr. Rao on the SOFT Trial in Patients With Premenopausal Breast Cancer
Author(s):
In Partnership With:
Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.
Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.
Updated results from the SOFT trial presented by Gini F. Fleming, MD, showed that the addition of ovarian suppression benefited patients with premenopausal breast cancer. The trial enrolled approximately 3000 patients who were randomized into 1 of 3 arms. Patients were randomized to either tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression.
The analysis compared tamoxifen with tamoxifen plus ovarian suppression and found that there was a significantly improved disease-free survival for these patients. This was especially true in the patients who had received prior chemotherapy, notes Rao.
